Foghorn Therapeutics (Nasdaq: FHTX) has announced that its partner, Eli Lilly (NYSE: LLY), has selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development.
The company plans to file an investigational new drug (IND) application for FHD-909 in the coming months, with a primary target patient population of certain people with non-small cell lung cancer (NSCLC).
FHD-909 is a highly potent, allosteric and orally available small molecule which has shown significant anti-tumor activity across multiple BRG1-mutant lung tumors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze